$29.57
0.44%
NYSE, Oct 16, 04:43 pm EDT. Closed.
ISIN
US7170811035
Symbol
PFE

Pfizer Stock News

Neutral
●
Business Wire
●
5 days ago
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) will present data from more than 50 company-sponsored, investigator-sponsored and collaborative research abstracts across its infectious disease pipeline and portfolio at the upcoming IDWeek 2026 congress, held in Washington, D.C., from October 21-24, 2026. Data across 12 oral presentations will showcase the Company's advancements in the preven...
Negative
●
WSJ
●
6 days ago
Regulators allege the ex-drug executive held more than 60 pharmaceutical stocks despite a court order barring him from the industry.
Neutral
●
Business Insider
●
6 days ago
The Federal Trade Commission said Martin Shkreli is still trading pharmaceutical stocks. The FTC said the "Pharma Bro" continues to do this despite a lifetime ban.
Neutral
●
Business Wire
●
6 days ago
PARIS--(BUSINESS WIRE)-- #Biotech--Enodia Therapeutics, a biotechnology company developing novel small-molecule therapies for targeted protein degradation at the point of synthesis, today announced it has entered into a research collaboration and license agreement with Pfizer Inc. to discover and develop Sec61 inhibitors. The collaboration aims to accelerate the discovery and advancement of nov...
Neutral
●
Business Wire
●
12 days ago
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved TUKYSA® (tucatinib) in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable locally advanced or metastatic human epidermal growth factor 2-positive (HER2+) breast cancer following induction treatment. The approval expan...
Negative
●
Reuters
●
12 days ago
Pfizer will cut around 330 jobs in Italy at its Sicily plant, ​labour unions said on Wednesday, making ‌the US drugmaker the latest international company downsizing its Italian operations.
Neutral
●
PRNewsWire
●
12 days ago
–  PADCEV™ (enfortumab vedotin) plus pembrolizumab data highlight durable survival benefit in advanced bladder cancer – – VYLOY™ (zolbetuximab) research reinforces the role of CLDN18.2 in shaping gastric cancer treatment decisions – TOKYO, Oct. 6, 2026 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that 21 abstracts from its oncolo...

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today